| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director | President and CEO
2 companies
Ramesh Kumar last filed a Form 4 in June 2023, as President and CEO at TRAW. The filings on record cover 2 companies. Ramesh Kumar's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
Historically, Ramesh Kumar's trades have earned a strong insider score of 80/100 across 7 rated trades. Over a 12-month horizon, all 7 of those trades were profitable, with an average 12-month return of +69.3%.
At the last filing, the largest reported position was 102,227 shares of TRAW. Net of sales, the TRAW filings show accumulation of 23,810 shares.
Ramesh Kumar has 23 Form 4 filings on record from April 2015 to June 2023, across 2 companies: Director at Ocugen (OCGN), 2020–2023; Chief Executive Officer at Traws Pharma (TRAW), 2015–2018.
The 30 reported transactions were 14 option or other derivative awards, 7 option exercises, 7 open-market sales and 1 open-market purchase, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $50K and 7 sales worth about $228K.
The only open-market purchase was 23,810 shares of TRAW at an average $2.10 on April 26, 2017, about $50K.
The largest open-market sale was 7,500 shares of OCGN at an average $8.13 on October 18, 2021, about $61K. Twelve months later OCGN was down 80%.
Shares as reported in the last Form 4 for each company; the most recent is from June 2023. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 6, 2022 | OCGN Ocugen, Inc. | Director | Sale+OE | 4,500 | $1.83 | $8,235.00 | - | -26.1% | -77.4% | |
| Jul 18, 2022 | OCGN Ocugen, Inc. | Director | Sale+OE | 7,500 | $2.57 | $19,275.00 | - | -33.1% | -75.9% | |
| Apr 18, 2022 | OCGN Ocugen, Inc. | Director | Sale+OE | 7,500 | $2.83 | $21,225.00 | - | -4.6% | -66.3% | |
| Jan 18, 2022 | OCGN Ocugen, Inc. | Director | Sale+OE | 7,500 | $4.07 | $30,525.00 | - | -35.0% | -69.8% | |
| Oct 18, 2021 | OCGN Ocugen, Inc. | Director | Sale+OE | 7,500 | $8.13 | $60,975.00 | - | -51.6% | -80.1% | |
| Jul 19, 2021 | OCGN Ocugen, Inc. | Director | Sale+OE | 7,500 | $6.40 | $48,000.00 | - | +9.8% | -64.0% | |
| Apr 19, 2021 | OCGN Ocugen, Inc. | Director | Sale+OE | 7,500 | $5.33 | $39,975.00 | - | +33.3% | -52.0% | |
| Apr 26, 2017 | TRAW Traws Pharma, Inc. | President and CEO | Buy | 23,810 | $2.10 | $50,001.00 | +30.4% | - | - |